Background: Inflammatory disease activity in patients with systemic lupus erythrematosus (SLE) may affect the development of atherosclerosis,contributing to their increased risk of cardiovascular disease(CVD). This process may be mediated by anti-apolipoprotein A-I(anti-Apo-AI) and anti-high density lipoprotein(anti-HDL) autoantibodsies. This study examines whether levels of these antibodies rise in association with increased SLE disease activity. Methods: IgG anti-HDL and anti-Apo-AI, lipid profile, MDA levels,PON activityand TAC were measured in serum from the following groups:50 patients with assessment of disease activity by SLEDAI scoreand 25 healthy controls. Results: Serum levels of IgG anti-HDL (67.4 ±14)and anti-Apo-AI (39.6 ±8.5) were higher in patients with SLE than in controls (p-value < 0.05)And they were higher in those with CVD.MDA level was significantly higher among cases (19.2 ±5). Paroxenase (PON) activity and Total antioxidant capacity (TAC) were lower in cases (46.5 ±8.9 and176.8 ±49.7 respectively) compared to controls (p-value < 0.05). Conclusion: A significant increase in IgG anti-HDL and anti-Apo-AI in patients with SLE and highly related to dyslipidemia.